Retinoids, RAMBAs, and Histone Deacetylase Inhibitors

类维生素A、RAMBA 和组蛋白脱乙酰酶抑制剂

• 批准号: 6963335
• 负责人: VINCENT Collins Ofuka NJAR
• 金额: $ 19.16万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6963335
• 关键词: SCID mouse; amidohydrolases; angiogenesis; apoptosis; athymic mouse; biological signal transduction; cell differentiation; cell line; cell proliferation; combination chemotherapy; drug discovery /isolation; enzyme inhibitors; gene expression; hydroxamate; neoplasm /cancer chemotherapy; neoplastic cell; neoplastic growth; nonhuman therapy evaluation; prostate neoplasms; retinoate; SCID mouse; amidohydrolases; angiogenesis; apoptosis; athymic mouse; biological signal transduction; cell differentiation; cell line; cell proliferation; combination chemotherapy; drug discovery /isolation; enzyme inhibitors; gene expression; hydroxamate; neoplasm /cancer chemotherapy; neoplastic cell; neoplastic growth; nonhuman therapy evaluation; prostate neoplasms; retinoate

DESCRIPTION (provided by applicant): All-trans retinoic acid (ATRA), a derivative of vitamin A (retinol), is required for the appropriate cellular proliferation and differentiation of normal human prostate epithelial cells. Human prostate cancer cells contain much lower levels of ATRA than normal cells. We hypothesize that aberrant metabolism of ATRA and dysregulation of gene expression in prostate tumor cells are related to the abnormal growth properties of the tumor cells. A rationale for using retinoic acid in prostate cancer therapy is further supported by the effectiveness of ATRA in the treatment of acute promyelocytic leukemia (APL). We hypothesize that the efficacy of ATRA can be enhanced if it is administered in combination with retinoic acid metabolism blocking agents (RAMBAs) plus low doses of selective histone deacetylase inhibitors (HDACIs) such as trichostatin A(TSA) or suberoylanilide hydroxamic acid (SAHA). HDACIs will act by sensitizing prostate cancer cells towards ATRA differentiation activity. The discovery of the retinoic acid receptor (RAR)/ADAC complex provides a rationale for combining RAs and HADCIs. The goals of this proposal are to use in vitro cell culture and also mouse xenograft models to ascertain the effectiveness of ATRA, various RAMBAs plus HDACIs in inhibiting the growth and inducing the differentiation of the human prostate cell lines, LNCaP, LAPC-4, PC-3 and DU-145. A second goal of the project is to understand at the molecular level the mechanisms by which the combination treatments result in human prostate tumor cell growth inhibition. These studies may provide a much clearer rationale for new clinical treatments for prostate cancer in humans. If this approach appears successful, we will consider the need for developing novel HDAC inhibitors in the subsequent RO1 proposal on the strengths of our expertise in drug design, discovery and development. The long-term goal of this project is to develop compounds with characteristics that are likely to provide effective antitumor activity against androgen-dependent and androgen independent prostatic cancer. The following specific aims that are proposed should enable us obtain substantial data that may support our hypothesis.

描述（由申请人提供）：适当的细胞增殖和正常人前列腺上皮细胞的适当细胞增殖和分化是必需的。人类前列腺癌细胞的ATRA水平比正常细胞低得多。我们假设ATRA的异常代谢和前列腺肿瘤细胞中基因表达的失调与肿瘤细胞的异常生长特性有关。 ATRA在治疗急性前临床白血病（APL）中的有效性进一步支持了在前列腺癌治疗中使用视黄酸的理由。我们假设如果ATRA与视黄酸代谢阻断剂（Rambas）以及低剂量的选择性组蛋白脱乙酰基酶抑制剂（HDACIS）（例如Trichostatin A（TSA）A（TSA）A（TSA）或Suberoylanilide hydroxamic Acide acrication（Sahaha），则可以增强ATRA的功效。 HDACIS将通过将前列腺癌细胞敏感到ATRA分化活性来起作用。视黄酸受体（RAR）/ADAC复合物的发现提供了组合Ras和Hadcis的理由。该提案的目标是使用体外细胞培养和小鼠异种移植模型来确定ATRA，各种Rambas Plus HDACI在抑制生长和诱导人类前列腺细胞系的分化，LNCAP，LAPC-4，PC-3，PC-3和DU-145方面的有效性。该项目的第二个目标是在分子水平上了解联合处理导致人前列腺肿瘤细胞生长抑制的机制。这些研究可能为人类前列腺癌的新临床治疗提供了更明显的理由。如果这种方法看起来成功，我们将考虑需要在随后的RO1提案中开发新型HDAC抑制剂，以了解我们在药物设计，发现和开发方面的专业知识的优势。该项目的长期目标是开发具有特征的化合物，这些化合物可能会提供有效的抗肿瘤活性，以针对雄激素依赖性和雄激素独立的前列腺癌。提出的以下具体目标应使我们获得可能支持我们假设的大量数据。